|
KMID : 0614720150580030209
|
|
Journal of Korean Medical Association
2015 Volume.58 No. 3 p.209 ~ p.215
|
|
|
Treatment for unresectable gastric cancer
|
|
Kim Tae-Yong
Oh Do-Youn
Bang Young-Jue
|
|
|
Abstract
|
|
|
|
Systemic chemotherapy is the cornerstone of treatment for patients with advanced gastric cancer. The combination of fluoropyrimidine and platinum is the most widely used first-line treatment worldwide. In patients with HER2-positive gastric cancer, the combination of trastuzumab (an anti-HER2 monoclonal antibody) and chemotherapy is the standard-of-care. Second-line chemotherapy can also prolong patients’ survival after progression; treatment options include cytotoxic chemotherapy (paclitaxel, docetaxel or irinotecan) and/or ramucirumab (an anti-VEGFR2 monoclonal antibody). A number of new targeted-agents are currently being studied, and more personalized approaches will be realized in the near future.
|
|
|
KEYWORD
|
|
|
Stomach neoplasms, Neoplasm metastasis, Drug therapy
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
 
|